Friday, September 27, 2013

Myriad Genetics' myplan™ lung cancer test meets primary clinical endpoint

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be a valuable tool for selecting which early-stage patients should be considered for additional post-surgical chemotherapy. "Lung cancer remains one of the most difficult-to-treat cancers...

No comments:

Post a Comment